Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Drug

Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma

Fineline Cube May 21, 2026
Company

Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales

Fineline Cube Jul 19, 2024

Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its...

Company Drug

Sino Biopharmaceutical Submits Market Approval Filing for CDK2/4/6 Inhibitor Culmerciclib in Breast Cancer

Fineline Cube Jul 19, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced the submission...

Company Drug

Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management

Fineline Cube Jul 19, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...

Hospital Policy / Regulatory R&D

China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing

Fineline Cube Jul 19, 2024

China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome...

Company Drug

China’s NMPA Suspends Daewoong Bio’s Cefodizime Over Inspection Refusal

Fineline Cube Jul 19, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Company Drug

Bain Capital-Backed Tenacia Wins NMPA Approval for Ganaxolone Oral Suspension for CDKL5 Deficiency

Fineline Cube Jul 19, 2024

Tenacia, a central nervous system (CNS) specialist company incubated by Bain Capital, has announced that...

Company Medical Device

MicroPort MedTech’s Vepack Filter Retriever Earns NMPA Marketing Approval

Fineline Cube Jul 19, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...

Company Medical Device

Venus Medtech’s VenusP-Valve Receives Marketing Approval in Venezuela, Expanding Global Reach

Fineline Cube Jul 19, 2024

Venus Medtech (Hangzhou) Inc., (HKG: 2500), a leading medical device company, has announced that it...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers

Fineline Cube Jul 19, 2024

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has...

Company Medical Device

Shanghai Sanyou Medical’s Cervical Thoracic Internal Fixation System Earns NMPA Approval

Fineline Cube Jul 19, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a leading medical device company based in China,...

Company Deals

Suzhou New District Hi-tech Industrial Co., Ltd and Subsidiaries to Establish Biopharmaceutical FOF with SND Group

Fineline Cube Jul 19, 2024

Suzhou New District Hi-tech Industrial Co., Ltd (SHA: 600736), a prominent company in China’s high-tech...

Company Deals

NeuShen Therapeutics and Livzon Pharma Strike Deal for Greater China Rights to NS-041

Fineline Cube Jul 19, 2024

NeuShen Therapeutics, a Sino-US biopharmaceutical company, has entered into a licensing agreement with Livzon Pharmaceutical...

Policy / Regulatory

NHSA Mandates Standardized Online Procurement for Injectable Drugs to Ensure Pricing Transparency

Fineline Cube Jul 18, 2024

The National Healthcare Security Administration (NHSA) has issued a directive to standardize the procurement process...

Company Drug

Consun Pharmaceutical Gets NMPA Go-Ahead for CKD Drug Clinical Trial

Fineline Cube Jul 18, 2024

Consun Pharmaceutical Group Ltd (HKG: 1681), a leading Chinese pharmaceutical company, has announced that it...

Company Drug

Shanghai Ruijin Hospital’s Hainan Subsidiary Adopts ANI Pharmaceuticals’ Veregen for HPV Treatment

Fineline Cube Jul 18, 2024

ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented...

Company Deals

Roche’s Genentech Terminates Relay Therapeutics Collaboration for SHP2 Inhibitor

Fineline Cube Jul 18, 2024

In a recent development, Roche Inc.’s subsidiary Genentech has given notice of termination for a...

Company

Johnson & Johnson Reports Robust Q2 2024 Earnings, Bolstered by Pharma and Medtech Growth

Fineline Cube Jul 18, 2024

Johnson & Johnson (NYSE: JNJ) has reported its financial results for the second quarter of...

Company Deals

Shanghai Escugen and Sidewinder Therapeutics Form Strategic Alliance for ADC Development

Fineline Cube Jul 18, 2024

Shanghai Escugen, a leading biopharmaceutical company specializing in antibody drug conjugates (ADCs), has announced a...

Company Drug

Junshi Biosciences’ Loqtorzi Inches Closer to Expanded Indication with NMPA Filing Acceptance

Fineline Cube Jul 18, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has taken a significant step forward...

Company Deals

SYNYI.AI Secures New Funding to Accelerate Digital Transformation in Healthcare

Fineline Cube Jul 18, 2024

Shanghai’s SYNYI.AI, a pioneering medical data mining and governance platform, has reportedly closed a new...

Posts pagination

1 … 331 332 333 … 669

Recent updates

  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
  • Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Company Medical Device

Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.